Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irbesartan

FDA-approved product (tablet, oral), marketed as Avapro, Irbesartan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Irbesartan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Chronic renal failure syndrome
  • Diabetic nephropathy
  • Hypertension
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
FDA pharmacologic class
Angiotensin 2 Receptor Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irbesartan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irbesartan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Angiotensin II Antagonist in Severe Sepsis

    NCT01992796 · start 2014-01

    Registered record
    Registry ID
    NCT01992796
    Conditions
    Severe Sepsis
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2017-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Sepsis
    InterventionIrbesartan
    PhasePhase 3
    Registry statusUnknown

  • The Oxford Marfan Trial

    NCT01949233 · start 2013-10

    Registered record
    Registry ID
    NCT01949233
    Conditions
    Marfan Syndrome
    Interventions
    Irbesartan 150-300mg capsules daily for 6 months; Doxycycline 100-200mg capsules daily for 6 months; Doxycycline placebo capsules daily for 6 months; Irbesartan placebo capsules daily for 6 months
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-10
    Completion
    2017-12
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarfan Syndrome
    InterventionIrbesartan 150-300mg capsules daily for 6 months; Doxycycline 100-200mg capsules daily for 6 months; Doxycycline placebo capsules daily for 6 months; Irbesartan placebo capsules daily for 6 months
    PhasePhase 2
    Registry statusUnknown

  • Sevelamer in Proteinuric CKD

    NCT01968759 · start 2013-10

    Registered record
    Registry ID
    NCT01968759
    Conditions
    Chronic Kidney Disease
    Interventions
    Sevelamer; Ramipril and Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2015-10
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionSevelamer; Ramipril and Irbesartan
    PhasePhase 2
    Registry statusCompleted

  • Preeclampsia: A Marker for Future Cardiovascular Risk in Women

    NCT01519297 · start 2012-05

    Registered record
    Registry ID
    NCT01519297
    Conditions
    Preeclampsia; Pregnancy Induced Hypertension
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Suspended
    Start
    2012-05
    Completion
    2019-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreeclampsia; Pregnancy Induced Hypertension
    InterventionIrbesartan
    PhaseNot applicable
    Registry statusSuspended

  • Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

    NCT01625494 · start 2012-05

    Registered record
    Registry ID
    NCT01625494
    Conditions
    Hypertension
    Interventions
    Irbesartan/Amlodipine (150/5mg); Irbesartan/Amlodipine (150/10mg); Irbesartan/Amlodipine (300/5mg); Irbesartan/Amlodipine (300/10mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2013-01
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan/Amlodipine (150/5mg); Irbesartan/Amlodipine (150/10mg); Irbesartan/Amlodipine (300/5mg); Irbesartan/Amlodipine (300/10mg)
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

    NCT01360710 · start 2012-01

    Registered record
    Registry ID
    NCT01360710
    Conditions
    Abdominal Obesity; Hypertension
    Interventions
    Moxonidine; Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-01
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbdominal Obesity; Hypertension
    InterventionMoxonidine; Irbesartan
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

    NCT01442987 · start 2011-05

    Registered record
    Registry ID
    NCT01442987
    Conditions
    Hypertension; Hyperlipidemia
    Interventions
    Irbesartan/Atorvastatin A; Irbesartan; Atorvastatin A; Placebo; Irbesartan/Atorvastatin B; Atorvastatin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-05
    Completion
    2013-05
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Hyperlipidemia
    InterventionIrbesartan/Atorvastatin A; Irbesartan; Atorvastatin A; Placebo +2 more
    PhasePhase 3
    Registry statusCompleted

  • Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy

    NCT00957554 · start 2009-07

    Registered record
    Registry ID
    NCT00957554
    Conditions
    Hypertension
    Interventions
    irbesartan/amlodipine; irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-07
    Completion
    2010-09
    Enrolment
    435

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionirbesartan/amlodipine; irbesartan
    PhasePhase 3
    Registry statusCompleted

  • Remission Clinic in Proteinuric Chronic Nephropathies

    NCT02721342 · start 2009-06

    Registered record
    Registry ID
    NCT02721342
    Conditions
    Chronic Kidney Disease
    Interventions
    Ramipril, Irbesartan and Atorvastin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2009-06
    Completion
    2022-11
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionRamipril, Irbesartan and Atorvastin
    PhaseNot recorded
    Registry statusUnknown

  • Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment

    NCT00741585 · start 2008-09-01

    Registered record
    Registry ID
    NCT00741585
    Conditions
    Essential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    Interventions
    Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09-01
    Completion
    2018-06-30
    Enrolment
    21,983

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Cardiovascular Disease; Stroke; Chronic Kidney Disease
    InterventionAny antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination; Ambulatory blood pressure monitoring
    PhasePhase 4
    Registry statusCompleted

  • ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination

    NCT00708344 · start 2008-06

    Registered record
    Registry ID
    NCT00708344
    Conditions
    Hypertension
    Interventions
    Irbesartan - Hydrochlorothiazide; Irbesartan - Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-07
    Enrolment
    832

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan - Hydrochlorothiazide; Irbesartan - Hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

    NCT01712126 · start 2007-09

    Registered record
    Registry ID
    NCT01712126
    Conditions
    Hypertension
    Interventions
    Irbesartan and Hydrochlorothiazide; Avalide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan and Hydrochlorothiazide; Avalide
    PhaseNot applicable
    Registry statusCompleted

  • Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions

    NCT01712139 · start 2007-09

    Registered record
    Registry ID
    NCT01712139
    Conditions
    Hypertension
    Interventions
    Irbesartan and Hydrochlorothiazide; Avalide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-09
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan and Hydrochlorothiazide; Avalide
    PhaseNot applicable
    Registry statusCompleted

  • Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan

    NCT00517322 · start 2007-08

    Registered record
    Registry ID
    NCT00517322
    Conditions
    Left Atrial Volume; Hypertensive Heart Disease; Antihypertensive Drugs; Diastolic Function; Renin Angiotensin System
    Interventions
    ramipril; irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2007-08
    Completion
    2010-08
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeft Atrial Volume; Hypertensive Heart Disease; Antihypertensive Drugs; Diastolic Function +1 more
    Interventionramipril; irbesartan
    PhasePhase 4
    Registry statusUnknown

  • Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

    NCT01712113 · start 2007-08

    Registered record
    Registry ID
    NCT01712113
    Conditions
    Hypertension
    Interventions
    Irbesartan; Avapro
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-08
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan; Avapro
    PhaseNot applicable
    Registry statusCompleted